AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $258.50, with a market capitalization of 462.49B. The stock trades at a price-to-earnings (P/E) ratio of 125.47 and offers a dividend yield of 2.65%.
On 2026-07-24, AbbVie(ABBV) stock traded between a low of $256.77 and a high of $260.19. Shares are currently priced at $258.50, which is +0.7% above the low and -0.6% below the high.
AbbVie(ABBV) shares are trading with a volume of 4.09M, against a daily average of 5.37M.
During the past year, AbbVie(ABBV) stock moved between $187.62 at its lowest and $261.64 at its peak.
During the past year, AbbVie(ABBV) stock moved between $187.62 at its lowest and $261.64 at its peak.
ABBV News
...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Supporting his choice, Canaccord Genuity analyst Gary Nachman maintained AbbVie with a Buy rating on Wednesday and raised the price target from $273 to $282. J...
HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points By David Beren Published Jul 23, 3:35PM EDT Quick Read HDV's 60% payout ratio and 9% divide...
Key Points AbbVie's shift towards immunology treatments points to continued dividend growth for this pharmaceutical stock. Chevron's efforts at financial disc...
Analyst Asad Haider from Goldman Sachs maintained a Hold rating on AbbVie and keeping the price target at $244.00. Claim 55% Off TipRanks Unlock powerful invest...
Key Points These healthcare leaders can navigate almost any economic environment. They have increased their payouts for a combined 118 years straight. 10 sto...
Earlier this month, Allergan Aesthetics, an AbbVie company, received European Commission approval for Boey (trenibotulinumtoxinE), the first rapid-onset, short-...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.